Search - tctmd.com

Displaying 161 - 180 of 254

Sort: Relevancy | Date

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Conference News EAS 2017

EAS Consensus Document Strives to Banish Skepticism Over LDL Cholesterol’s Causal Role in Atherosclerosis

Yael L. Maxwell

April 24, 2017

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Todd Neale

February 24, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Michael O'Riordan

January 05, 2017

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

Advertisement

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Alirocumab Price Slashed in Deal With Express Scripts

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Ischemic Heart Disease the Leading Cause of Death Globally

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

EAS Consensus Document Strives to Banish Skepticism Over LDL Cholesterol’s Causal Role in Atherosclerosis

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content